NCT04392830View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 11, 2020

Primary Completion Date

April 28, 2021

Study Completion Date

June 15, 2021

Conditions
Healthy
Interventions
DRUG

ALZ002 DS

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (1)

5000

Cmax clinical research, Adelaide

Sponsors
All Listed Sponsors
lead

AnnJi Pharmaceutical Co., Ltd.

INDUSTRY

NCT04392830 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers | Biotech Hunter | Biotech Hunter